Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia

Recruiting now · Early Phase 1

Conditions studied: Androgenetic Alopecia (AGA)

In brief

The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Androgenetic Alopecia (AGA) in female adults. The main question it aims to answer is: • Does DHA increase terminal hair follicles in the vertex area. Researchers will compare oral DHA plus topical minoxidil to topical minoxidil alone in female patients with AGA to see if DHA works to alleviate AGA. Participants will: * Receive oral DHA every day plus topical minoxidil or use topical minoxidil alone for 6 months. * Visit the clinic once every month for checkups and tests.

Key facts

Study ID

NCT07012486

Run by

Shanghai Zhongshan Hospital

People needed

30

Starts

2025-06-01

Expected to finish

2026-12-01

Last updated by the study team

2025-06-10

Who can join

Age: 18 and older, up to 40. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Clinically diagnosed with androgenetic alopecia (AGA)
• No pregnancy plans within the next 6 months

You may not qualify if…

• Patients who received systemic medications for hair loss within the past 2 months
• Use of topical medication for hair loss within the past 2 weeks
• Pregnancy or lactation
• Patients with known severe diseases of vital organs (e.g., heart, liver, kidney) or malignancies.

Where it is running

• Zhongshan Hospital Fudan University — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.